Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

  1. Girard, N.
  2. Bar, J.
  3. Garrido, P.
  4. Garassino, M.C.
  5. McDonald, F.
  6. Mornex, F.
  7. Filippi, A.R.
  8. Smit, H.J.M.
  9. Peters, S.
  10. Field, J.K.
  11. Christoph, D.C.
  12. Sibille, A.
  13. Fietkau, R.
  14. Haakensen, V.D.
  15. Chouaid, C.
  16. Markman, B.
  17. Hiltermann, T.J.N.
  18. Taus, A.
  19. Sawyer, W.
  20. Allen, A.
  21. Chander, P.
  22. Licour, M.
  23. Solomon, B.
Aldizkaria:
Journal of Thoracic Oncology

ISSN: 1556-1380,  1556-0864

Argitalpen urtea: 2023

Alea: 18

Zenbakia: 2

Orrialdeak: 181-193

Mota: Artikulua

DOI: 10.1016/J.JTHO.2022.10.003 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus